These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39168966)

  • 1. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
    Zhang M; Bzura A; Baitei EY; Zhou Z; Spicer JB; Poile C; Rogel J; Branson A; King A; Barber S; Kamata T; Dzialo J; Harber J; Greystoke A; Nusrat N; Faulkner D; Sun Q; Nolan L; Hahne JC; Scotland M; Walter H; Darlison L; Morgan B; Bajaj A; Brookes C; Hollox EJ; Lubawska D; Jama M; Griffiths G; Nakas A; Kutywayo K; Luo JL; Klampatsa A; Cooper A; Halder K; Wells-Jordan P; Zhou H; Dudbridge F; Thomas A; Richards CJ; Pritchard C; Yang H; Barer M; Fennell DA
    Nat Commun; 2024 Aug; 15(1):7187. PubMed ID: 39168966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
    Raghav K; Liu S; Overman MJ; Willett AF; Knafl M; Fu SC; Malpica A; Prasad S; Royal RE; Scally CP; Mansfield PF; Wistuba II; Futreal AP; Maru DM; Solis Soto LM; Parra Cuentas ER; Chen H; Villalobos P; Verma A; Mahvash A; Hwu P; Cortazar P; McKenna E; Yun C; Dervin S; Schulze K; Darbonne WC; Morani AC; Kopetz S; Fournier KF; Woodman SE; Yao JC; Varadhachary GR; Halperin DM
    Cancer Discov; 2021 Nov; 11(11):2738-2747. PubMed ID: 34261675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
    Homicsko K; Zygoura P; Norkin M; Tissot S; Shakarishvili N; Popat S; Curioni-Fontecedro A; O'Brien M; Pope A; Shah R; Fisher P; Spicer J; Roy A; Gilligan D; Rusakiewicz S; Fortis E; Marti N; Kammler R; Finn SP; Coukos G; Dafni U; Peters S; Stahel RA
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37880184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F; Bironzo P; Righi L; Listì A; Arizio F; Novello S; Volante M; Scagliotti GV
    Clin Lung Cancer; 2021 Jan; 22(1):e63-e66. PubMed ID: 32917522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
    Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
    Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Nojima Y; Shimizu K; Saisho S; Maeda AI; Kurosaki T; Kurose K; Oga T; Oka M; Nakata M
    Anticancer Res; 2021 Nov; 41(11):5469-5475. PubMed ID: 34732416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
    Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
    Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
    Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
    Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
    Minchom A; Yuan W; Crespo M; Gurel B; Figueiredo I; Wotherspoon A; Miranda S; Riisnaes R; Ferreira A; Bertan C; Pereira R; Clarke M; Baker C; Ang JE; Fotiadis N; Tunariu N; Carreira S; Popat S; O'Brien M; Banerji U; de Bono J; Lopez J
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
    Inaguma S; Ueki A; Lasota J; Komura M; Sheema AN; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Schrump DS; Hassan R; Miettinen M; Takahashi S
    J Pathol Clin Res; 2023 May; 9(3):195-207. PubMed ID: 36754859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy.
    Harber J; Kamata T; Pritchard C; Fennell D
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
    Minnema-Luiting J; Vroman H; Aerts J; Cornelissen R
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29601534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
    Seto T; Nosaki K; Shimokawa M; Toyozawa R; Sugawara S; Hayashi H; Murakami H; Kato T; Niho S; Saka H; Oki M; Yoshioka H; Okamoto I; Daga H; Azuma K; Tanaka H; Nishino K; Tohnai R; Yamamoto N; Nakagawa K
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35105689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.